Han Rui, Sun Yifang, Su Mingshan
All authors are affiliated with the Dermatology, Su Medical Cosmetic Clinic, Beijing, China.
Dermatol Surg. 2025 May 1;51(5):485-489. doi: 10.1097/DSS.0000000000004545. Epub 2025 Jan 7.
The effectiveness and safety of 730-nm picosecond laser for treating acquired bilateral nevus of Ota-like macules remain uncertain.
This study aims to evaluate the potential benefits and risks of using the 730-nm picosecond laser for ABNOM removal.
This is a retrospective review of patients who were presented to the clinic between January 2020 and January 2024 for the treatment of ABNOM with 730-nm picosecond laser alone. The efficacy of the laser was assessed based on the Quartile Improvement Scale, using high-resolution photographs evaluated by blinded dermatologists.
A total of 72 Chinese participants with Fitzpatrick skin types III to IV were included in the study. The overall effective rate of the treatment was 75%, achieved after an average of 2.42 ± 0.75 sessions. A subgroup analysis of 41 patients who completed 3 treatment sessions showed statistically significant differences in outcomes across the sessions. The mean improvement scores for sessions 1, 2, and 3 were 1.63 ± 1.04, 2.66 ± 1.22, and 3.29 ± 1.17, respectively ( p < .01). No cases of hypopigmentation were observed. The incidence of postinflammatory hyperpigmentation was 5.56%.
The 730-nm picosecond laser is a safe and effective treatment for ABNOM in Chinese patients.
730纳米皮秒激光治疗获得性双侧太田痣样斑的有效性和安全性尚不确定。
本研究旨在评估使用730纳米皮秒激光去除获得性双侧太田痣样斑的潜在益处和风险。
这是一项回顾性研究，研究对象为2020年1月至2024年1月期间仅使用730纳米皮秒激光到诊所治疗获得性双侧太田痣样斑的患者。激光的疗效基于四分位数改善量表进行评估，使用由不知情的皮肤科医生评估的高分辨率照片。
本研究共纳入72名皮肤类型为Fitzpatrick III至IV型的中国参与者。治疗的总有效率为75%，平均经过2.42±0.75次治疗后达到。对41名完成3次治疗的患者进行的亚组分析显示，各次治疗的结果存在统计学显著差异。第1、2和3次治疗的平均改善分数分别为1.63±1.04、2.66±1.22和3.29±1.17（p<.01）。未观察到色素减退病例。炎症后色素沉着的发生率为5.56%。
730纳米皮秒激光对中国患者的获得性双侧太田痣样斑是一种安全有效的治疗方法。
